|
Sign In to gain access to subscriptions and/or personal tools.
|
Phenolphthalein Induces Thymic Lymphomas Accompanied by Loss of the p53 Wild Type Allele in Heterozygous p53-Deficient (±) Mice
June K. Dunnick
National Institute of Environmental Health Sciences
Jerry F. Hardisty
Experimental Pathology Laboratories, Inc.
Ronald A. Herbert
National Institute of Environmental Health Sciences
John C. Seely
PATHCO, Inc.
E. Marianna Furedi-Machacek
Integrated Laboratory Systems, Research Triangle Park, North Carolina
Julie F. Foley
National Institute of Environmental Health Sciences
Gregory D. Lacks
Integrated Laboratory Systems, Research Triangle Park, North Carolina
Stanley Stasiewicz
National Institute of Environmental Health Sciences
John E. French
National Institute of Environmental Health Sciences
Epidemiology studies have indicated that many human cancers are influenced by environmental factors. Genetically altered mouse model systems offer us the opportunity to study the interaction of chemicals with genetic predisposition to cancer. Using the heterozygous p53-deficient (±) mouse, an animal model carrying one wild type p53 gene and one p53 null allele, we studied the effects of phenolphthalein on tumor induction and p53 gene alterations. Earlier studies showed that phenolphthalein caused carcinogenic effects in Fisher 344 rats and B6C3F, mice after a 2-yr dosing period (Dunnick and Hailey, Cancer Res. 56: 4922-4926, 1996). The p53 (±) mice received phenolphthalein in the feed at concentrations of 200, 375, 750, 3,000, or 12,000 ppm (approximately 43, 84, 174, 689, or 2,375 mg/kg body weight/day or 129, 252, 522, 2,867, or 7,128 mg/m2 body surface area/day) for up to 6 mo. A target organ cancer site that accumulated p53 protein in the B6C3F, mouse (i.e., thymic lymphoma) was also a target site for cancer in the p53 (±) mouse. In the p53 (±) mouse, treatment-related atypical hyperplasia and malignant lymphoma of thymic origin were seen in the control and dosed groups at a combined incidence of 0, 5, 5, 25, 100, and 95%, respectively. Twenty-one of the thymic lymphomas were examined for p53 gene changes, and all showed loss of the p53 wild type allele. Chemical-induced ovarian tumors in the B6C3F, mouse showed no evidence for p53 protein accumulation and did not occur in the p53 (±) mouse. The p53-deficient (±) mouse model responded to phenolphthalein treatment with a carcinogenic response in the thymus after only 4 mo of dosing. This carcinogenic response took 2 yr to develop in the conventional B6C3F, mouse bioassay. The p53-deficient (±) mouse is an important model for identifying a carcinogenic response after short-term (<6 mo) exposures. Our studies show that exposure to phenolphthalein combined with a genetic predisposition to cancer can potentiate the carcinogenic process and cause p53 gene alterations, a gene alteration found in many human cancers.
Key Words: p53 • phenolphthalein • p53-deficient (±) mice • thymic lymphoma • carcinogenesis
Toxicologic Pathology, Vol. 25, No. 6,
533-540 (1997)
DOI: 10.1177/019262339702500601
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. D. Cardiff, M. R. Anver, G. P. Boivin, M. W. Bosenberg, R. R. Maronpot, A. A. Molinolo, A. Y. Nikitin, J. E. Rehg, G. V. Thomas, R. G. Russell, et al.
Precancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers
Toxicol Pathol,
October 1, 2006;
34(6):
699 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Stoll, K. T. Blanchard, J. H. Stoltz, J. B. Majeska, S. Furst, P. D. Lilly, and J. H. Mennear
Phenolphthalein and Bisacodyl: Assessment of Genotoxic and Carcinogenic Responses in Heterozygous p53 (+/-) Mice and Syrian Hamster Embryo (SHE) Assay
Toxicol. Sci.,
April 1, 2006;
90(2):
440 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takizawa, T. Imai, J.-i. Onose, M. Ueda, T. Tamura, K. Mitsumori, K. Izumi, and M. Hirose
Enhancement of Hepatocarcinogenesis by Kojic Acid in Rat Two-Stage Models after Initiation with N-bis(2-hydroxypropyl)nitrosamine or N-diethylnitrosamine
Toxicol. Sci.,
September 1, 2004;
81(1):
43 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morton, R. S. Sellers, S. M. Furst, K. D. Hawley, and J. R. May
Effect of Oral Gavage Dosing Regimens in Female Tg rasH2 Transgenic Mice
Toxicol Pathol,
June 1, 2004;
32(4):
413 - 417.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Takizawa, K. Mitsumori, T. Tamura, M. Nasu, M. Ueda, T. Imai, and M. Hirose
Hepatocellular Tumor Induction in Heterozygous p53-Deficient CBA Mice by a 26-Week Dietary Administration of Kojic Acid
Toxicol. Sci.,
June 1, 2003;
73(2):
287 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Shirai, T. Tsukamoto, M. Yamamoto, T. Iidaka, H. Sakai, T. Yanai, T. Masegi, L. A. Donehower, and M. Tatematsu
Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis
Carcinogenesis,
September 1, 2002;
23(9):
1541 - 1547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Floyd, P. Mann, G. Long, and R. Ochoa
The Trp53 Hemizygous Mouse in Pharmaceutical Development: Points to Consider for Pathologists
Toxicol Pathol,
January 1, 2002;
30(1):
147 - 156.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. E. Hulla, J. E. French, and J. K. Dunnick
Chromosome 11 Loss from Thymic Lymphomas Induced in Heterozygous Trp53 Mice by Phenolphthalein
Toxicol. Sci.,
April 1, 2001;
60(2):
264 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Hulla, J. E. French, and J. K. Dunnick
Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice
Carcinogenesis,
January 1, 2001;
22(1):
89 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. French, G. D. Lacks, C. Trempus, J. K. Dunnick, J. Foley, J. Mahler, R. R. Tice, and R. W. Tennant
Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent
Carcinogenesis,
January 1, 2001;
22(1):
99 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Storer, J. E. French, J. Haseman, G. Hajian, E. K. Legrand, G. G. Long, L. A. Mixson, R. Ochoa, J. E. Sagartz, and K. A. Soper
p53 +/- Hemizygous Knockout Mouse: Overview of Available Data
Toxicol Pathol,
January 1, 2001;
29(1_suppl):
30 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. F. Coogan, L. Rosenberg, J. R. Palmer, B. L. Strom, A. G. Zauber, P. D. Stolley, and S. Shapiro
Phenolphthalein Laxatives and Risk of Cancer
J Natl Cancer Inst,
December 6, 2000;
92(23):
1943 - 1944.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamamoto, T. Tsukamoto, H. Sakai, N. Shirai, H. Ohgaki, C. Furihata, L. A. Donehower, K. Yoshida, and M. Tatematsu
p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis
Carcinogenesis,
October 1, 2000;
21(10):
1891 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Collins, T. B. Grizzle, and J. K. Dunnick
Toxicokinetics of Phenolphthalein in Male and Female Rats and Mice
Toxicol. Sci.,
August 1, 2000;
56(2):
271 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Delker, B. L. Yano, and B. B. Gollapudi
Evaluation of Cytotoxicity, Cell Proliferation, and Genotoxicity Induced by p-Cresidine in Hetero- and Nullizygous Transgenic p53 Mice
Toxicol. Sci.,
June 1, 2000;
55(2):
361 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Boley, E. E. Anderson, J. E. French, L. A. Donehower, D. B. Walker, and L. Recio
Loss of p53 in Benzene-induced Thymic Lymphomas in p53+/- Mice: Evidence of Chromosomal Recombination
Cancer Res.,
June 1, 2000;
60(11):
2831 - 2835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gulezian, D. Jacobson-Kram, C. B. Mccullough, H. Olson, L. Recio, D. Robinson, R. Storer, R. Tennant, J. M. Ward, and D. A. Neumann
Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment
Toxicol Pathol,
May 1, 2000;
28(3):
482 - 499.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Mitsumori, H. Onodera, T. Shimo, K. Yasuhara, H. Takagi, T. Koujitani, M. Hirose, C. Maruyama, and S. Wakana
Rapid induction of uterine tumors with p53 point mutations in heterozygous p53-deficient CBA mice given a single intraperitoneal administration of N-ethyl-N-nitrosourea
Carcinogenesis,
May 1, 2000;
21(5):
1039 - 1042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Spalding, J. E. French, S. Stasiewicz, M. Furedi-Machacek, F. Conner, R. R. Tice, and R. W. Tennant
Responses of Transgenic Mouse Lines p53+/- and Tg•AC to Agents Tested in Conventional Carcinogenicity Bioassays
Toxicol. Sci.,
February 1, 2000;
53(2):
213 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Mahler, N. D. Flagler, D. E. Malarkey, P. C. Mann, J. K. Haseman, and W. Eastin
Spontaneous and Chemically Induced Proliferative Lesions in Tg.AC Transgenic and p53-Heterozygous Mice
Toxicol Pathol,
July 1, 1998;
26(4):
501 - 511.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. Weaver, J. F. Contrera, B. A. Rosenzweig, K. L. Thompson, P. J. Faustino, J. M. Strong, C. D. Ellison, L. W. Anderson, H. R. Prasanna, P. E. Long-Bradley, et al.
An Evaluation of the Hemizygous Transgenic Tg.AC Mouse for Carcinogenicity Testing of Pharmaceuticals. I. Evidence for a Confounding Nonresponder Phenotype
Toxicol Pathol,
July 1, 1998;
26(4):
532 - 540.
[Abstract]
[PDF]
|
|
|
|
|
